Summary: In a randomised trial in ischemic heart disease, combination therapy with a statin, an SGLT2 inhibitor, and a PCSK9 inhibitor produced the largest lipid reduction over 12 months, exceeding each agent used alone, with age and sex modestly modifying the response.
PICO Summary
| Element | Detail |
|---|---|
| Population | 500 adults with established ischemic heart disease; multicentre 12-month randomised trial. |
| Intervention | Combination therapy: statin plus SGLT2 inhibitor plus PCSK9 inhibitor. |
| Comparison | Monotherapy arms: statin alone, SGLT2 inhibitor alone, or PCSK9 inhibitor alone. |
| Outcome | All arms reduced lipids at 12 months; the combination achieved the greatest reduction (-74±10 mg/dL, p<0.05). Age and sex slightly modulated the response. The study measured lipid parameters, not cardiovascular events. |
Disease-Modifying Drugs and Lipids in IHD
RCT · ischemic heart disease · 12 months
Triple therapy lowered lipids more than any single agent over 12 months. The trial measured lipids, not cardiovascular events.
Expert Commentary
This trial confirms what mechanism predicts and what guidelines increasingly demand: stacking lipid-lowering agents with complementary actions yields additive LDL reduction, and the triple combination drove cholesterol down furthest. The pharmacology is logical, statins cut synthesis and upregulate LDL receptors, PCSK9 inhibitors stop those receptors being degraded, and the combination amplifies receptor-mediated clearance, while the SGLT2 inhibitor contributes little to lipids but earns its place through independent cardiorenal benefit. For very high-risk secondary prevention, where targets of LDL below 55 mg/dL are often unreachable on a statin alone, this supports aggressive combination regimens. My main caveat is what the study did not measure: it reports lipid levels, not cardiovascular events, so the clinical value of the extra lowering must be borrowed from the outcome trials of each class rather than demonstrated here, and the specific drugs and doses within each class are not detailed. Can I use this with my patients? Yes, in line with current practice. For a patient with coronary disease not at LDL goal on a maximally tolerated statin, it reinforces adding a PCSK9 inhibitor to reach target and using an SGLT2 inhibitor for its cardiorenal protection, while monitoring response and individualising by patient factors.
References
Mohammad N, Darweesh O, Merkhan M. The impact of disease-modifying medications on the lipid profile of patients with ischemic heart disease. Georgian Med News. 2025;(363):175–178. PMID: 40884383